Adaptimmune

Adaptimmune is a biotechnology company that researches and develops T-cell receptors for the treatment of cancer and infectious diseases.

Business Model:

Revenue: $17.5M

Employees: 201-500

Detailed Adaptimmune Information

Geographic Data

Adaptimmune headquarters map

Address: 60 Jubilee Avenue

City: Oxfordshire

State: england

Zip: OX14 4RX

Country: GB

Financial Info

Stage:

post ipo equity

Raised Last:

$150M

Raised Total:

$400M

Metrics

2,675,315Website Global Rank

6,565Website Monthly Traffic

Twitter Followers

Description

Adaptimmune is a biotechnology company that researches and develops T-cell receptors for the treatment of cancer and infectious diseases.

Contact Phone:

Contact Email:

Adaptimmune went public on 5/6/2015 on the NASDAQ

Listed Exchange:
NASDAQ

IPO Date:
5/6/2015

IPO Valuation:
$1B

Ticker Symbol:
ADAP

Amount Raised:
$191M

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
Announced Date Transaction Number of Investors Money Raised Lead Investors
2/2015 Venture Round 1 - Eight Roads Ventures
Eight Roads Ventures
3/2017 Post-IPO Equity $60.1M
1/2014 Venture Round 1 - Sahsen Ventures
Sahsen Ventures
4/2017 Post-IPO Equity $42M
5/2015 IPO $191.3M
9/2014 Series A $0 Merlin Nexus
F-Prime Capital
Wellington Management
Ridgeback Capital
University of Oxford
Foresite Capital
Novo Holdings
venBio Partners
New Enterprise Associates
QVT Financial
OrbiMed
Rock Springs Capital
Merlin Nexus
F-Prime Capital
Wellington Management
Ridgeback Capital
University of Oxford
Foresite Capital
Novo Holdings
venBio Partners
New Enterprise Associates
QVT Financial
OrbiMed
Rock Springs Capital
9/2014 Series A $103.8M New Enterprise Associates
OrbiMed Advisors LLC
Wellington Management Company
Fidelity Biosciences
Foresite Capital
Ridgeback Capital Management
Novo A/S
QVT Financial LP
Rock Springs Capital
venBio
University of Oxford
9/2018 Post-IPO Equity $100M
3/2014 Grant 1 $3.5M Biomedical Catalyst Fund
9/2021 Post-IPO Equity 1 $150M Genentech
Genentech
2/2015 Venture Round 1 - Eight Roads Ventures
Eight Roads Ventures
9/2014 Series A 12 $104M Merlin Nexus
F-Prime Capital
Wellington Management
Ridgeback Capital
University of Oxford
Foresite Capital
Novo Holdings
venBio Partners
New Enterprise Associates
Merlin Nexus
F-Prime Capital
Wellington Management
Ridgeback Capital
University of Oxford
Foresite Capital
Novo Holdings
venBio Partners
New Enterprise Associates
1/2014 Venture Round 1 -
Announced Date Name Price

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research